Harmony Biosciences is trading 4.53% down at $31.00 in pre-market on November 6 after third-quarter earnings missed expectations. - Q3 earnings were $0.81 per share versus $1.00 consensus; revenue was $268.92 million, also slightly below estimates. - Higher research and development costs, milestone charges, and royalty expenses pressured profitability. - Shares fell 5.65% to $32.47 on November 5, on volume of 1,442,399 shares; pre-market volume was unavailable in sources reviewed.